Global Human Albumin Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Type;

5% Concentrations, 25% Concentrations, and Others.

By Application;

Therapeutics, Drug Formulation & Vaccine, Component of Media, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn994446785 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Human Albumin Market (USD Million), 2021 - 2031

In the year 2024, the Global Human Albumin Market was valued at USD 10,368.64 million. The size of this market is expected to increase to USD 19,322.48 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 9.3%.

Human albumin, a vital protein synthesized by the liver, plays a crucial role in maintaining oncotic pressure, transporting hormones, vitamins, and drugs, and regulating colloidal osmotic pressure. As a therapeutic agent, human albumin is indispensable in the treatment of various medical conditions, including hypovolemia, burns, hypoalbuminemia, and acute liver failure. It is also extensively used during surgeries and in the management of severe infections and trauma, where restoring and maintaining blood volume is critical.

One of the primary factors fueling the growth of the global human albumin market is the rising prevalence of chronic diseases and conditions such as liver cirrhosis, nephrotic syndrome, and cancer. The increasing incidence of these ailments, which often result in decreased albumin levels, has heightened the demand for albumin-based therapies. Additionally, the expanding geriatric population, which is more susceptible to such chronic conditions, further drives market growth. Advances in biopharmaceutical manufacturing techniques have enhanced the production and purification processes of human albumin, ensuring higher yield and purity. These technological improvements have not only boosted the supply but also reduced the risk of contamination, thereby increasing the safety and efficacy of albumin products.

The therapeutic applications of human albumin extend beyond its traditional uses. Emerging research and clinical trials are exploring its potential in new therapeutic areas, including as a drug delivery agent and in the treatment of neurological disorders and acute respiratory distress syndrome (ARDS). Such innovative applications are expected to open new avenues for market expansion.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Type
    2. Market Snapshot, By Application
    3. Market Snapshot, By Region
  4. Global Human Albumin Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Prevalence of Chronic Diseases

        2. High Adoption Rates in Developed Markets

        3. Rising Demand from the Biotechnology Sector

      2. Restraints
        1. High Cost of Production
        2. Risk of Transmission of Bloodborne Pathogens
      3. Opportunities
        1. Increased Demand in Biotechnology and Vaccine Development

        2. Increased Awareness and Diagnostic Rates

    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Human Albumin Market, By Type, 2021 - 2031 (USD Million)

      1. 5% Concentrations

      2. 25% Concentrations

      3. Others

    2. Global Human Albumin Market, By Application, 2021 - 2031 (USD Million)
      1. Therapeutics
      2. Drug Formulation & Vaccine
      3. Component of Media
      4. Others
    3. Global Human Albumin Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. CSL Behring

      2. Grifols

      3. Baxalta

      4. Octapharma

      5. Kedrion

  7. Analyst Views
  8. Future Outlook of the Market